Concepedia

Lauren Langbein

LL

Statistics

Publications

4

Citations

184

H-Index

4

Active since

2018

Affiliations

Thomas Jefferson University(Current)

Fox Chase Cancer Center

Sidney Kimmel Cancer Center

Yale University

Guangzhou Medical University

Lauren Langbein is an author at Thomas Jefferson University specializing in molecular oncology, oncology, and renal cell carcinoma.

ORCID

Publications per year

2018–2022

4

Publications

4

PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth

Weijia Cai, Liya Su, Lili Liao et al. · Nature Communications · 2019 · 79 citations · Full text

, , +15

BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma

Lauren Langbein, Rayan El Hajjar, He Shen et al. · Cancer Letters · 2022 · 36 citations · Full text

, , +17

Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer

Lili Liao, Zongzhi Liu, Lauren Langbein et al. · eLife · 2018 · 35 citations · Full text

, , +17

High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of <scp>PBRM</scp>1

Lili Liao, Nilda L. Alicea‐Velázquez, Lauren Langbein et al. · Molecular Oncology · 2018 · 34 citations · Full text

, , +11

1–4 of 4